Clinical Trials Directory

Trials / Conditions / Sintilimab

Sintilimab

21 registered clinical trials studyying Sintilimab — 9 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsa
NCT07506109
Tianjin Medical University Cancer Institute and HospitalPhase 2
RecruitingThiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Re
NCT07416890
Zhejiang Cancer HospitalPhase 2
RecruitingSintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824
Sun Yat-sen UniversityPhase 2
RecruitingThe Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the
NCT07138755
The Third Xiangya Hospital of Central South UniversityPhase 2
Not Yet RecruitingEfficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for
NCT06459921
Xijing HospitalPhase 2
RecruitingLow Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
NCT06714708
Anhui Provincial Cancer HospitalPhase 2
RecruitingSintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06413342
Zhejiang Cancer HospitalPhase 2
RecruitingbTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
NCT06070636
Sun Yat-sen UniversityN/A
Active Not RecruitingEfficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous
NCT06342167
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
RecruitingSintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
NCT05707819
Cancer Hospital of Guangxi Medical University—
UnknownSOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positiv
NCT05218148
Aiping ZhouPhase 2
UnknownPeri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
NCT04982939
Tianjin Medical University Cancer Institute and HospitalPhase 2
UnknownA Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer
NCT05105672
The Affiliated Hospital of Xuzhou Medical UniversityPhase 2
Active Not RecruitingNeoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSC
NCT05400070
Tang-Du HospitalPhase 2
CompletedHAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
NCT04618367
Sun Yat-sen UniversityN/A
UnknownSintilimab in FH-deficient Renal Cell Carcinoma
NCT04146831
West China HospitalPhase 2
CompletedAnlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
NCT04271813
Shanghai Changzheng HospitalPhase 2
UnknownSintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
NCT04023916
Chinese Academy of Medical SciencesPhase 2
UnknownSRS Sequential Sindilimab in Brain Metastasis of NSLSC
NCT04180501
Xiaorong DongPhase 2
UnknownSintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
NCT04213170
Sun Yat-sen UniversityPhase 2
CompletedCombined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
NCT03936452
Sun Yat-sen UniversityPhase 2